Publication Name	World Journal of Pharmacology
Manuscript ID	13758
Country	Finland

Received	2014-09-01 09:43
Peer-Review Started	2014-09-03 11:00
To Make the First Decision	2014-10-14 17:33
Return for Revision	2014-10-20 08:14
Revised	2014-11-18 01:31
Second Decision	2015-01-09 19:31
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-01-19 13:27
Articles in Press	2015-01-19 13:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-09 18:32
Publish the Manuscript Online	2015-03-12 19:39

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Importance of microenvironment in preclinical models of breast and prostate cancer
Manuscript Source	Invited Manuscript
All Author List	Maija Valta, Katja Fagerlund, Mari Suominen, Jussi Halleen and Johanna Tuomela
Funding Agency and Grant Number	Funding Agency Grant Number Eurostars program of Eureka
Corresponding Author	Johanna Tuomela, PhD, Adjunct Professor, Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland. jomitu@utu.fi
Key Words	Tumor microenvironment; Breast cancer; Prostate cancer; Preclinical; Efficacy
Core Tip	It is today a recognized major problem in cancer drug development that the vast majority of drugs entering clinical trials fail to reach the market due to poor efficacy. One important reason for this is the wide use of subcutaneous xenograft models that are cheap, fast and easy to perform, but lack tumor microenvironment. Concentrating on breast and prostate cancer, we explain why the presence of tumor microenvironment is important, and describe different types of preclinical efficacy models that incorporate tumor microenvironment. We state the importance of using these models to reduce the high failure rates in clinical trials.
Publish Date	2015-03-12 19:39
Citation	Valta M, Fagerlund K, Suominen M, Halleen J, Tuomela J. Importance of microenvironment in preclinical models of breast and prostate cancer. World J Pharmacol 2015; 4(1): 47-57
URL	http://www.wjgnet.com/2220-3192/full/v4/i1/47.htm
DOI	http://dx.doi.org/10.5497/wjp.v4.i1.47

Full Article (PDF)	WJP-4-47.pdf
Full Article (Word)	WJP-4-47.doc
Manuscript File	13758-Review.docx
Answering Reviewers	13758-Conflict of interest statement.pdf
Conflict-of-Interest Disclosure Form	13758-Conflict of interest statement.pdf
Copyright License Agreement	13758-Copyright assignment.pdf
Peer-review Report	13758-Peer-review(s).pdf
Scientific Misconduct Check	13758-CorssCheck.jpg
Scientific Editor Work List	13758-Scientific editor work list.pdf